Filtering options
Pharma
MedTech
EU
US
M&A
CDD/VDD
Asia-Pac
Biotech
CDMO
Medical Devices
Pharma EU M&A

Aesculapius Farmaceutici Srl sells to Ceres Pharma NV

Alira Health advised Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC drugs, food supplements and raw materials, in the sale to Ceres Pharma. The transaction is expected to further expand Ceres Pharma’s presence in Italy and the business combination will create value for the pharmaceutical ecosystem via enhanced distributions and commercialization capabilities of the combined entity. We were honored to serve as a transaction advisor representing the seller in this landmark deal.
2024
Pharma CDD/VDD

CDD Advisor: Alcami acquires Pacific Pharmaceutical Services

Alira Health advised Alcami, a leading Contract Development Manufacturing Organization headquartered in North Carolina, with CDD support in its acquisition of PPS, a West Coast-based biostorage company. This investment will enable bicoastal geographic expansion of Alcami’s Pharma Storage and Services capabilities, thus allowing it to serve all US biotech and pharma hubs.
AliraHealth TVM DEBx
2023
CDD/VDD Medical Devices

CDD Advisor: TVM Capital Healthcare invests in DEBx Medical

Alira Health advised TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, with CDD support in its multi-million euro investment in DEBx Medical, an Amsterdam-based medical devices company. The investment will accelerate the introduction of the DEBx Medical solution, DEBRICHEM®, an innovative product for treating non-healing chronic wounds that is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds.
2023
MedTech US CDMO

Natech Plastic sells to Stratec SE

Alira Health advised Natech Plastic, a leading contract development and manufacturing company specialized in precision life sciences consumables, in the sale to Stratec SE. The transaction is expected to boost Stratec’s presence in the North American market and the business combination will create value for the in-vitro diagnostics ecosystem via enhanced innovation and manufacturing capabilities. We were honored to serve as the sellers’ advisors in this important deal.
Daiichi Subtipharm
2022
Pharma EU

Daiichi-Sankyo Europe sells to Substipharm

The sale of a non-strategic asset to Substipharm, will allow Daiichi Sankyo to repurpose its financial and operational resources on other value added products by developing and sourcing innovative products with strong competitive advantage in oncology.
Formycon_Athos 2022
2022
Pharma EU Biotech

Exclusive sell-side advisor: Formycon acquires Biosimilar Assets from ATHOS KG

Formycon has completed the full acquisition of biosimilar candidate FYB202 (ustekinumab) and acquisition of a 50% stake in biosimilar candidate FYB201 (ranibizumab) as well as the takeover of the operational development unit Bioeq GmbH. Alira Health acted as the sell-side advisor to the sellers.
Haemotronic GVS Transaction
2022
MedTech EU CDMO

Exclusive sell-side advisor: GVS acquires Haemotronic

GVS has finalized the acquisitions of Haemotronic, a company specializing in medical device components and products. Alira Health represented the sellers in the transaction, which establishes an Italy-based, global leader of specialty manufacturing solutions to the healthcare and life sciences markets.
Asahi Kasei_Bionova_Transaction
2022
Pharma US CDMO

Exclusive buy-side advisor: Asahi Kasei acquires Bionova Scientific

Asahi Kasei Medical has finalized the acquisition of Bionova Scientific, a company specializing in contract development and GMP-compliant manufacturing services for biopharmaceutical companies. Alira Health represented the buyer in the transaction, contributing unique know-how of drug development, quality, and operations that was critical for the deal completion.
Load more
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.